Ramipril prior to thrombolysis attenuates the early increase of PAI-1 in patients with acute myocardial infarction

Thrombosis and Haemostasis

Volumn 88, Issue 2, 2002, Pages 180-185

  Wagner, Andreas ^a   Herkner, Harald ^a   Schreiber, Wolfgang ^a   Bur, Andreas ^a   Woisetschläger, Christian ^a   Stix, Günther ^a   Laggner, Anton N ^a   Hirschl, Michael M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Myocardial infarction; Ramipril; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CREATINE KINASE; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEPARIN; NITRATE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAMIPRIL;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOT LYSIS; BLOOD SAMPLING; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRESSLER SYNDROME; DRUG EFFECT; DRUG POTENTIATION; ELECTROCARDIOGRAPHY MONITORING; FEMALE; FIBRINOLYSIS; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REPERFUSION INJURY; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION; STATISTICAL SIGNIFICANCE; THORAX PAIN;

EID: 0036335433     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613185     Document Type: Article

References (22)

1. Endothelial function, fibrinolysis, and angiotensin-converting enzyme inhibition
2. Angiotensin II regulates the expression of plasminogen activator inhibitor in cultured endothelial cells
3. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function
4. Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
5. Effects of an angiotensin-convertin-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
6. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). 1999 updated: ACC AHA guidelines for the management of patients with acute myocardial infarction
7. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis
8. Attenuation of thrombolysis-induced increase of plasminogen activator inhibitor-1 by intravenous enalaprilat
9. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
10. Prediction of early complications in patients with acute myocardial infarction by calculation of the ST score
11. Continuous 12-led ST-segment recovery analysis in the TAMI-7 study group. Performance of a noninvasive method for real-time detection of failed mayocardial reperfusion
12. The Thrombolysis in Myocardial Infarction (TIMI) trial: Phase I findings
13. Recombinant lys-plasminogen given before, but not after recombinant tissue-type plasminogen activator markedly improves coronary thrombolysis in dogs: Relationship of thrombolytic efficacy with parameters of fibrinolysis
14. Augmentation of plasminogen activator inhibitor type 1 activity in plasma by thrombosis and by thrombolysis
15. Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration
16. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction
17. Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study)
18. Induction of plasminogen activator inhibitor by products released from platelets
19. Plasminogen activator inhibitor in plasma: Risk factors for recurrent myocardial infarction
20. Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction
21. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke
22. Correlation between plasminogen activator inhibitor-1 (PAI-1) and infarct size in acute myocardial infarction